Ceftazidime-avibactam is an intravenously administered combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam. ceftazidime-avibactam is approved for the treatment of adults with complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia (HAP), and other infections caused by aerobic. This article discusses the in vitro activity and pharmacological properties of ceftazidime-avibactam, and reviews data on the agent’s clinical efficacy and tolerability relating to use in these indications. Ceftazidime-avibactam has excellent in vitro activity against many important Gram-negative pathogens, including many extended-spectrum. It is not active against metallo-β-lactamase-producing strains. Ceftazidime-avibactam treatment was associated with high response rates at the test-of-cure visit in patients with infections caused by ceftazidime-susceptible and - nonsusceptible Gram-negative pathogens. Ceftazidime-avibactam was generally well tolerated, with a safety and tolerability profile consistent with that of ceftazidime alone and that was generally typical of the injectable cephalosporins. Thus, ceftazidime-avibactam represents a valuable new treatment option for these serious and difficult-to-treat infections.